Latest news
Novo Nordisk (CPSE:NOVO B) Reports Mixed ZEUS Phase 3 Results For Ziltivekimab - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 19:09:11 GMTZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients - TCTMD.comTCTMD.com · Mon, 03 Aug 2026 17:05:08 GMTNovo’s late-stage IL-6 stumble shakes inflammation space - BioSpaceBioSpace · Mon, 03 Aug 2026 11:36:04 GMTWeekly Recap: ZEUS miss lifts BGE-102 and Analysts cut BIOA PTs, keep Buy - TradingViewTradingView · Mon, 03 Aug 2026 11:33:16 GMTNovo Nordisk Plummets 10 Percent After Heart Drug ZEUS Trial Fails - streamlinefeed.co.kestreamlinefeed.co.ke · Mon, 03 Aug 2026 07:30:40 GMTZEUS delivers a bolt of pain to Novo Nordisk - pharmaphorumpharmaphorum · Mon, 03 Aug 2026 07:26:02 GMTNovo Nordisk's Phase 3 ZEUS trial misses cardiovascular endpoint for Ziltivekimab - Indian Pharma PostIndian Pharma Post · Sat, 01 Aug 2026 14:24:34 GMTNovo Nordisk's ZEUS Null Result: A €8 Billion Question Mark Over the Cardiovascular Strategy - AD HOC NEWSAD HOC NEWS · Sat, 01 Aug 2026 14:22:13 GMT